COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?

MeSH terms

• Angiotensin Receptor Antagonists / adverse effects*
• Angiotensin Receptor Antagonists / therapeutic use
• Angiotensin-Converting Enzyme 2
• Angiotensin-Converting Enzyme Inhibitors / adverse effects*
• Angiotensin-Converting Enzyme Inhibitors / therapeutic use
• Animals
• Antihypertensive Agents / adverse effects*
• Antihypertensive Agents / therapeutic use
• Betacoronavirus*
• COVID-19
• Coronavirus Infections / complications*
• Coronavirus Infections / epidemiology
• Humans
• Hypertension / complications
• Hypertension / drug therapy*
• Lung Injury / drug therapy
• Lung Injury / enzymology
• Mice
• Pandemics
• Peptidyl-Dipeptidase A / drug effects
• Peptidyl-Dipeptidase A / metabolism
• Pneumonia, Viral / complications*
• Pneumonia, Viral / epidemiology
• SARS-CoV-2
• Severe acute respiratory syndrome-related coronavirus / pathogenicity
• Vasodilation / physiology
• Virus Internalization